In the original article, there was a mistake in Figure 3H as published. An incorrect image for the p53 measurement in A549 was shown. The corrected Figure 3H appears below.
FIGURE 3
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
lung cancer, Platinum complex, Water solubility, ROS/p53 pathway, cisplatin resistance
Citation
Lin X, Jia Y, Dong X, Shen J, Jin Y, Li Y, Wang F, Anenberg E, Zhou J, Zhu J, Chen X, Xie Q and Xie Y (2022) Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance. Front. Pharmacol. 13:890886. doi: 10.3389/fphar.2022.890886
Received
07 March 2022
Accepted
05 April 2022
Published
28 April 2022
Volume
13 - 2022
Edited and reviewed by
Fabrizio Marcucci, University of Milan, Italy
Updates
Copyright
© 2022 Lin, Jia, Dong, Shen, Jin, Li, Wang, Anenberg, Zhou, Zhu, Chen, Xie and Xie.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yicheng Xie, ycxie@zju.edu.cn
‡ These authors have contributed equally to this work
† Present Address: Xixi Lin, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.